Intravenous immunoglobulin therapy for resistant ocular Behçet's disease

Br J Ophthalmol. 2001 Nov;85(11):1287-8. doi: 10.1136/bjo.85.11.1287.

Abstract

Aims: The present report was aimed at finding out whether gammaglobulin could have a role in treating ocular Behçet's disease (BD) refractory to accepted medical therapy.

Methods: Six eyes of four patients with ocular BD refractory to steroids and cyclosporin A were treated with a course of intravenous gammaglobulin and followed up for their response to treatment.

Results: All six eyes of all four patients showed good response to gammaglobulin therapy.

Conclusion: Gamma globulin may have a role in treating refractory ocular BD. A wide range of controlled studies with longer follow up is needed to substantiate this impression.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Adult
  • Behcet Syndrome / complications
  • Behcet Syndrome / therapy*
  • Cyclosporine / therapeutic use
  • Drug Administration Schedule
  • Female
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Panuveitis / etiology
  • Panuveitis / therapy*
  • Treatment Failure
  • Treatment Outcome

Substances

  • Glucocorticoids
  • Immunoglobulins, Intravenous
  • Immunosuppressive Agents
  • Cyclosporine